Physician profile
Mitchell D Weinstein
NPI 1093793440
$7,181.34
in general payments reported to CMS, 2019-2025
38 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $577 · 2021: $1,833 · 2022: $969 · 2023: $1,124 · 2024: $800 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $908.73 | 2019-2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $812.59 | 2021-2024 | Prolaris, Myrisk |
| Astellas Pharma US INC | $710.82 | 2019-2023 | Myrbetriq, Veozah |
| Endo Pharmaceuticals INC. | $638.12 | 2019-2022 | |
| Antares Pharma, INC. | $484.56 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $438.01 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $405.95 | 2021-2025 | |
| Abbvie INC. | $259.63 | 2020-2024 | |
| Blue Earth Diagnostics | $243.36 | 2019-2024 | |
| Olympus America INC. | $226.65 | 2020-2021 | |
| Myovant Sciences INC. | $220.05 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $218.54 | 2019-2022 | |
| Endo USA, INC. | $174.63 | 2024-2025 | Xiaflex |
| Ferring Pharmaceuticals INC. | $155.03 | 2019-2025 | Adstiladrin |
| Coloplast Corp | $154.30 | 2020-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.